ArticleInternational journal of clinical pharmacy2025

Cost-effectiveness analysis of glofitamab versus rituximab for relapsed or refractory diffuse large B-cell lymphoma patients in China.

Hanrui Zheng et al.PubMed ↗Publisher ↗

No numbers read from the abstract.